VIA Pharmaceuticals Inc (CE) (VIAP) 銘柄情報

07/26/2021 08:00:00 VIAP
VIA Pharmaceuticals, Inc. Common Stock
T3
Other OTC
Trade Resume

VIAP SEC Suspension "due to a lack of accurate and adequate public information about the companies because questions have arisen as to their operating status, if any."

https://www.sec.gov/litigation/suspensions/2021/34-92362.pdf

Order:

https://www.sec.gov/litigation/suspensions/2021/34-92362-o.pdf

$VIAP Volume

My wife is still holding in her portfolio until full clarification is made.
I personally bailed out years ago and broke out even.

out

Is anybody still holding onto their stocks with VIA Pharmaceuticals?

I've seen the other posts which appears that we have been duped.

Just wondering if anyone else is holding or selling.

The markets are broken...

"What's ours is ours, and what's yours is ours"... just isn't sustainable.

Participation in the markets is already at generational lows...

Real investment is dead.

Trading scrip while the music still plays is all that's left..

YEP. You hit the nail on its head. Another retailer screwing end. They did it in a very dirty way. Yet no challenge. They even stole shell value. I bet they will resurface the co with different shel nme or sale IP asset of VIAP.

..............

And, go figure... Bay City has Madrigal listed in their portfolio companies... but doesn't have VIAP listed in their "past performers"... LOL!!!

Looks like they basically robbed the VIAP shareholders... kept the assets intact and took them for themselves, and tossed the OTHER investors aside. By taking VIAP off into the dark corners of the market to hide the dirty deed they were doing... they even destroyed the value of the shell by de-registering it...

They could at least have been honest about it... and TOLD you they were foreclosing on the debt and screwing over those investors who had trusted them ?

Sure doesn't do very much to instill confidence in Bay City... and their treatment of their investors...

Here, it looks like they have a solid enough project... they're even KEEPING it... but, too bad so sad for the investors ?

VERY shabby... and rots a ruck to them...

That sort of piss poor performance... gives them a failing grade in my book. Those who are watching ? Doing your people wrong like that... will likely cost them far more in lost opportunities than they'll ever recognize.

Next...

That, and they'd previously filed a form 15 in March of 2011.

So it looks like VIAP is officially dead... at least dead enough that they didn't think it would be necessary to bother telling shareholders that they'd been screwed...

Madrigal Pharmaceuticals, Inc. acquired the assets of VIA Pharmaceuticals in September 2011

http://www.viapharmaceuticals.com/

Agree. It's startling to see that they'd not already been turned into a pumpkin back then... but, then, that news was almost seven months ago ? So... ???

VIA 0.04 PHARMACEUTICALS INITIATES PHASE I DYSLIPIDEMIA TRIAL. Amazing still alive and kicking.


Jun 13, 2011 (Datamonitor via COMTEX) -- VIA Pharmaceuticals, Inc., a biotechnology company, has announced dosing of the first healthy volunteers in a Phase I clinical trial of VIA-3196, the company's orally administered, liver-directed thyroid hormone, or THR, beta receptor agonist for the treatment of high LDL cholesterol and other dyslipidemias including high triglycerides and elevated Lp(a).

As a beta-selective THR agonist, VIA-3196 is designed to specifically target receptors in the liver involved in metabolism and cholesterol regulation, and avoid side effects associated with THR activation outside the liver. In preclinical studies, VIA-3196 demonstrated a rapid reduction of non-HDL cholesterol, triglycerides, and fatty liver, and synergistic activity when used with statins.

The Phase I clinical trial of VIA-3196 is an ascending single-dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of VIA-3196 in healthy subjects. The single-center trial will enroll approximately seventy-two subjects and is being conducted by Cetero Research at its clinical study site in Fargo, ND. VIA-3196 was first developed by Hoffmann-La Roche Inc. and inlicensed by VIA Pharmaceuticals in December 2008.

"There remains a significant unmet need for new and more effective therapies that reduce the lipids linked to heart disease, particularly among high risk patients whose LDL cholesterol is not controlled by current therapies," said Rebecca Taub, MD, Senior vice president, R&D for VIA Pharmaceuticals. "By targeting a distinct mechanism of lipid metabolism, VIA-3196 has the potential to address hypercholesterolemia and other dyslipidemias when given alone or in combination with other lipid lowering agents. We are pleased that the first volunteers have been dosed with the study drug and no adverse events have been reported."
http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon..

Filed 15-12G in March... and no one noticed.

SO, I guess that's what you call a dead stock.

New ticker symbol VIAP:OTN
http://www.marketwatch.com/investing/stock/VIAP

VIA Pharmaceuticals Announces First-in-Human Dosing of VIA-3196 for Treatment of Dyslipidemia
print
Via Pharmaceuticals (PN) (USOTC:VIAP)
Historical Stock Chart

6 Months : March 2011 to September 2011
Click Here for more Via Pharmaceuticals (PN) Charts.

VIA Pharmaceuticals, Inc. (PINKSHEETS: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced dosing of the first healthy volunteers in a Phase I clinical trial of VIA-3196, the Company's orally administered, liver-directed thyroid hormone (THR) beta receptor agonist for the treatment of high LDL cholesterol and other dyslipidemias including high triglycerides and elevated Lp(a).

As a beta-selective THR agonist, VIA-3196 is designed to specifically target receptors in the liver involved in metabolism and cholesterol regulation, and avoid side effects associated with THR activation outside the liver. In preclinical studies, VIA-3196 demonstrated a rapid reduction of non-HDL cholesterol, triglycerides, and fatty liver, and synergistic activity when used with statins.

"There remains a significant unmet need for new and more effective therapies that reduce the lipids linked to heart disease, particularly among high risk patients whose LDL cholesterol is not controlled by current therapies," said Rebecca Taub, MD, Senior Vice President, Research & Development for VIA Pharmaceuticals. "By targeting a distinct mechanism of lipid metabolism, VIA-3196 has the potential to address hypercholesterolemia and other dyslipidemias when given alone or in combination with other lipid lowering agents. We are pleased that the first volunteers have been dosed with the study drug and no adverse events have been reported."

"Today's announcement is a significant milestone for VIA Pharmaceuticals, and an important first step in the clinical development of VIA-3196," said Lawrence Cohen, PhD, Chief Executive Officer of VIA Pharmaceuticals.

The Phase I clinical trial of VIA-3196 (ClinicalTrials.gov ID: NCT01367873) is an ascending single-dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of VIA-3196 in healthy subjects. The single-center trial will enroll approximately seventy-two subjects and is being conducted by Cetero Research at its clinical study site in Fargo, ND. VIA-3196 was first developed by Hoffmann-La Roche Inc. and inlicensed by VIA Pharmaceuticals in December 2008.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases. VIA's drug candidates include VIA-3196 and other compounds to address underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

That is probably the "nicest" if least useful description of a "take down" as I've ever read... which still doesn't make it anything other than exactly that ?

Interesting take on VIAP by a longer:
http://seekingalpha.com/instablog/457722-la-stock-talk/62733-viap-via-pharmaceuticals-inc

Time to die meter... clocks are ticking more loudly.

According to the terms of the 2010 Loan Agreement, the debt is due to the Lenders on December 31, 2010.

The 2010 Notes are secured by a lien on all of the assets of the Company. Amounts borrowed under the 2010 Notes accrue interest at the rate of 15% per annum, which increases to 18% per annum following an event of default.

Their recent report:

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS
1. ORGANIZATION
Overview — VIA Pharmaceuticals, Inc. (“VIA,” the “Company,” “we,” “our,” or “us”), incorporated in Delaware in June 2004 and headquartered in San Francisco, California, is a development stage biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. The Company is building a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic disease, including vascular inflammation, high cholesterol, high triglycerides and insulin sensitization/diabetes. During 2005, the Company in-licensed a small molecule compound, VIA-2291, which targets an unmet medical need of reducing atherosclerotic plaque inflammation, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Atherosclerosis, depending on its severity and the location of the artery it affects, may result in major adverse cardiovascular events (“MACE”), such as heart attack and stroke. During 2006, the Company initiated two Phase 2 clinical trials of VIA-2291 in patients undergoing a carotid endarterectomy (“CEA”), and in patients at risk for acute coronary syndrome (“ACS”). During 2007, the Company initiated a third Phase 2 clinical trial where ACS patients undergo Positron Emission Tomography with flurodeoxyglucose tracer (“FDG-PET”), an experimental non-invasive imaging technique to measure the effect of treatment of VIA-2291 on uptake of FDG into the vascular wall. Effective during the first quarter of 2009, the Company licensed from Hoffman-LaRoche Inc. and Hoffmann-LaRoche Ltd. (collectively “Roche”) the exclusive worldwide rights to two sets of compounds. The first license is for Roche’s thyroid hormone receptor beta agonist, a clinically ready candidate for the control of cholesterol, triglyceride levels and potential in insulin sensitization/diabetes. The second license is for multiple compounds from Roche’s preclinical diacylglycerol acyl transferase 1 metabolic disorders program.
Through June 30, 2010, the Company has been primarily engaged in developing initial procedures and product technology, screening and in-licensing of target compounds, clinical trial activity, and raising capital. To fund operations, VIA has been raising cash through debt, a merger and equity financings. The Company is organized and operates as one operating segment.
Merger — On June 5, 2007, Corautus completed a merger (the “Merger”) with privately-held VIA Pharmaceuticals, Inc. pursuant to the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated February 7, 2007, by and among Corautus, Resurgens Merger Corp., a Delaware corporation and a wholly owned subsidiary of Corautus (“Resurgens”), and privately-held VIA Pharmaceuticals, Inc. Pursuant to the Merger Agreement, Resurgens merged with and into privately-held VIA Pharmaceuticals, Inc., which continued as the surviving company as a wholly-owned subsidiary of Corautus. Immediately following the effectiveness of the Merger on June 5, 2007, privately-held VIA Pharmaceuticals, Inc. merged (the “Parent-Subsidiary Merger”) with and into Corautus, pursuant to which Corautus continued as the surviving corporation. Immediately following the Parent-Subsidiary Merger, Corautus changed its corporate name from “Corautus Genetics Inc.” to “VIA Pharmaceuticals, Inc.” Unless otherwise specified, as used throughout these unaudited condensed financial statements, the “Company,” “we,” “us,” and “our” refers to the business of the combined company after the merger (the “Merger”) with Corautus Genetics Inc. (“Corautus”) on June 5, 2007 and the business of privately-held VIA Pharmaceuticals, Inc. prior to the Merger. Unless specifically noted otherwise, as used throughout these unaudited condensed financial statements, “Corautus Genetics Inc.” or “Corautus” refers to the business of Corautus prior to the Merger.
Going Concern — From inception, the Company has incurred expenses in research and development activities without generating any revenues to offset those expenses and the Company does not expect to generate revenues in the near future. The Company has incurred losses and negative cash flow from operating activities from inception, and as of June 30, 2010, the Company had an accumulated net deficit of approximately $86.6 million. Until the Company can establish profitable operations to finance its cash requirements, the Company’s ability to meet its obligations in the ordinary course of business is dependent upon its ability to raise substantial additional capital through public or private equity or debt financings, the establishment of credit or other funding facilities, collaborative or other strategic arrangements with corporate sources or other sources of financing, the availability of which cannot be assured. On June 5, 2007, the Company raised $11.1 million through the Merger with Corautus to cover existing obligations and provide operating cash flows. In July 2007, the Company entered into a securities purchase agreement that provided for issuance of 10,288,065 shares of common stock for approximately $25.0 million in gross proceeds.


4

Table of Contents

As more fully described in Note 6 in the notes to the unaudited condensed financial statements, in March 2009, the Company entered into a Note and Warrant Purchase Agreement (the “Loan Agreement”) with its principal stockholder and one of its affiliates (the “Lenders”) whereby the Lenders agreed to lend to the Company in the aggregate up to $10.0 million. The Company secured the loan with all of its assets, including the Company’s intellectual property. On March 12, 2009, the Company borrowed the initial $2.0 million available under the Loan Agreement. Subsequently, the Company made $2.0 million borrowings under the Loan Agreement on May 19, 2009, June 29, 2009, August 14, 2009, respectively, and the Company borrowed the final $2.0 million available under the Loan Agreement on September 11, 2009. According to the terms of the original Loan Agreement, the debt was due to the Lenders on September 14, 2009. The parties agreed to extend the repayment terms on various dates in 2009, and on February 26, 2010, the Lenders agreed to modify the Loan Agreement to further extend the repayment terms to April 1, 2010. The Lenders did not modify the interest rate or offer any concessions in the amendments to the Loan Agreements. The Company failed to repay the debt and all related interest to the Lenders due on April 1, 2010.
As more fully described in Note 6 in the notes to the unaudited condensed financial statements, in March 2010, the Company entered into a second Note and Warrant Purchase Agreement (the “2010 Loan Agreement”) with its principal stockholder and one of its affiliates (the “Lenders”) whereby the Lenders agreed to lend to the Company in the aggregate up to $3.0 million, pursuant to the terms of promissory notes (collectively, the “2010 Notes”) delivered under the 2010 Loan Agreement. The Company secured the loan with all of its assets, including the Company’s intellectual property. On March 29, 2010, the Company borrowed the initial $1.25 million available under the 2010 Loan Agreement. Subsequently, the Company made $100,000, $200,000 and $300,000 borrowings under the 2010 Loan Agreement on May 26, 2010, June 4, 2010, and June 29, 2010, respectively. According to the terms of the 2010 Loan Agreement, the debt is due to the Lenders on December 31, 2010. As described in Note 14 in the notes to the unaudited condensed financial statements, the Company borrowed an additional $850,000 in subsequent borrowings in July 2010. Subject to the Lenders’ approval, the Company may borrow in the aggregate up to an additional $300,000 at subsequent closings pursuant to the terms of the 2010 Loan Agreement and 2010 Notes. The 2010 Notes are secured by a lien on all of the assets of the Company. Amounts borrowed under the 2010 Notes accrue interest at the rate of 15% per annum, which increases to 18% per annum following an event of default. Unless earlier paid in accordance with the terms of the 2010 Notes, all unpaid principal and accrued interest shall become fully due and payable on the earlier to occur of (i) December 31, 2010, (ii) the closing of a debt, equity or combined debt/equity financing resulting in gross proceeds or available credit to the Company of not less than $20,000,000, and (iii) the closing of a transaction in which the Company sells, conveys, licenses or otherwise disposes of a majority of its assets or is acquired by way of a merger, consolidation, reorganization or other transaction or series of transactions pursuant to which stockholders of the Company prior to such acquisition own less than 50% of the voting interests in the surviving or resulting entity.
The Company had $158,000 in cash at June 30, 2010. Subject to the Lenders’ approval, the Company may borrow in the aggregate up to an additional $300,000 at subsequent closings pursuant to the terms of the 2010 Loan Agreement. Management believes that, under normal continuing operations, the total amount of cash available under the 2010 Loan Agreement, if borrowed, will enable the Company to meet only a portion of its current obligations. Management does not believe that existing cash resources will be sufficient to enable the Company to meet its ongoing working capital requirements for the next twelve months and the Company will need to raise substantial additional funding in the near term to repay amounts owed under the Loan Agreement and 2010 Loan Agreement, and to meet its ongoing working capital requirements. As a result, there are substantial doubts that the Company will be able to continue as a going concern and, therefore, may be unable to realize its assets and discharge its liabilities in the normal course of business. The unaudited condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or to amounts and classifications of liabilities that may be necessary should the Company be unable to continue as a going concern.

VIAP 0.09 5K volume so far!

Reporting 100 k draw down from the fund
http://ih.advfn.com/p.php?pid=nmona&article=43127527&symbol=NO^VIAP

$010 now!

It is a nice article, but is doesn't appear to be major news to those here. We already knew "it worked"... based on the data presented at the end points of the studies. But, what the data showed was that it didn't actually work in quite the way that they had thought it would.

The new publication doesn't seem to obviously alter anything much... as far as the investment case is concerned...

The end point of the study left them with a positive result, but it left them also not knowing WHY the result was positive, generating a new need for them to move the base in "the science"... so that they had something actually standing there underneath the results, supporting their thesis re a mode of operation by which the benefit was generated.

A good result in terms of science... isn't necessarily a good result in terms of investment... Good for scientists to see the result, and good for patients that you do know how to address the bit of the problem you've shown you can. Not good for investors that you don't own the patent on the method by which the benefit is generated... given you don't KNOW the method by which the benefit is generated ?

One caveat... I haven't read the article... so can't claim I know the detail in what the article presents that is or might be different from the results of the studies previously announced.

They do lead with a statement suggesting that the results they show mean a Phase III investigation is justified.

I think to have that happen, they'll still need to move the pillar in the science in a way that there is a solid concept in a method of operation that is supported by the data, that also supports the case for Phase III.

Not clear to me that this actually does that...

Ya gotta admire their timing...

LOL!!!

Great question..

how come it hasn't moved?

VIA Pharmaceuticals and MHI Announce Publication of VIA-2291 5-Lipoxygenase Inhibitor Clinical Study Data in Circulation: Cardio
Date : 05/20/2010 @ 7:30AM
Source : MarketWire
Stock : VIA Pharmaceuticals (VIAP)
Quote : 0.16 0.0 (0.00%) @ 7:13AM


VIA Pharmaceuticals and MHI Announce Publication of VIA-2291 5-Lipoxygenase Inhibitor Clinical Study Data in Circulation: Cardio

SAN FRANCISCO, CA and MONTREAL -- (Marketwire)
05/20/10
VIA Pharmaceuticals, Inc. (PINKSHEETS: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, and The Montreal Heart Institute today announced the publication of clinical trial data from a study of VIA-2291, a 5-Lipoxygenase inhibitor (5-LO), in volume 3, issue 3 of the American Heart Association journal Circulation: Cardiovascular Imaging, published May 19, 2010.

"Despite standard-of-care treatment, patients with recent acute coronary syndromes remain at high risk of recurrent vascular events, and this risk is greater in patients with evidence of ongoing inflammation," said Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute Research Centre, professor of medicine at the University of Montreal, principal investigator of the VIA-2291 ACS trial and the lead author of the publication. "VIA-2291 is designed to target the underlying inflammatory disease process active in atherosclerosis, including the reduction of leukotrienes, an approach not addressed by currently available treatment. These newly published data strongly support the evaluation of VIA-2291 in larger outcome trials."

The publication includes data from VIA's ACS study, a randomized, double-blind, placebo controlled Phase 2 study of VIA-2291 in 191 patients who recently experienced acute coronary syndromes (ACS), including heart attack or unstable angina. Patients on standard care medications (statins, blood pressure medications, and platelet inhibitors) were treated once daily for 12 weeks with one of three doses of VIA-2291 or placebo. The study met its primary endpoint by demonstrating a statistically significant, dose-dependent inhibition of whole blood stimulated leukotriene LTB4 production at 12 weeks (P < 0.0001) demonstrating greater than 80% inhibition in 90% of patients. Leukotrienes are important mediators of inflammation believed to be involved in the development and progression of atherosclerotic plaque. VIA-2291 is designed to be a selective, potent and reversible inhibitor of 5-LO, a key enzyme in the biosynthesis of leukotrienes. A significant reduction of urine leukotriene LTE4, a marker of systemic leukotriene production, was also obtained in all dose groups, a secondary endpoint of the study. The drug was found to be well tolerated, with no serious adverse events considered related to study drug.

A subset of 93 patients were also evaluated in a 64-slice coronary CT examination at baseline and at 24 weeks to study VIA-2291's effect over a longer timeframe. Among evaluable patients, new coronary plaques were observed in 5 of 18 (27.8%) placebo and 2 of 42 (4.8%) VIA-2291-treated patients (P=0.01). A reduction in non-calcified plaque volume at 24 weeks versus placebo was observed in VIA-2291-treated groups in the patients in whom this endpoint was analyzable (P < 0.01).

Although unchanged at 12 weeks in the main study, concentrations of high-sensitivity C-reactive protein (hs-CRP), a validated marker of inflammation and risk for cardiovascular diseases, were reduced by 67% in the VIA-2291 100-mg treatment group relative to placebo at 24 weeks (P=0.0002) among patients in the extension sub-study.

The publication can be found on the American Heart Association's website at http://circimaging.ahajournals.org.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

About the Montreal Heart Institute

Founded in 1954 by Dr. Paul David, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in prevention, ultra-specialized care, professionals training, clinical and fundamental research, and assessment of new technologies. The Institute is part of a vast network of excellence in health formed by the Université de Montréal and its affiliated institutions. To learn more about the Institute, please visit our website at www.icm-mhi.org.

Huge news on VIAP today.

What is the status of the pending (since March 31, 2010) FDA approval of their drug going through clinical trials? I've not been able to find approval or denial info, and none of my news alerts have come up-so there is no decision on it-but perhaps there is a new date?

Good news, in my honest opinion, on this, could be a monster hit...since the drug is highly needed, so now COULD be a good time to buy in...of course, bad news...well, maybe its only worth a $200 or so buy in...because bad news is certain to take just about all the value out, too. So, its what I'd call a major strategic risk investment-not quite a gamble...but one heck of a risky move for any significant dollar investment.

Bay continues feeding them $... but they certainly aren't showing there is any reason for current investors to care or to support Bay in sustaining the focus it seems is being applied in the current effort, at least in terms of the investment. VIAP is already in hock to them well past the point of again being one of Bay's wholly owned portfolio companies... in all but the form.

No news I can see happening on the science side leaves the management of the effort and the value of the property as a shell the focus. Cutting to six employees hopefully means some new ability to parse the plan in terms of future focus and path. Are the six remaining a core science team who are continuing the R&D, or have they kept in that small core a management team that is there for operating the shell ?

Given the obligations they have... IF they end up developing anything of real value, there is huge risk that value is likely to end up being transferred out to some other Bay operated vehicle or in a deal to an outsider in partial settlement of the outstanding obligations.

Attachment of any value that exists to a VIAP share is obviously not something you can count on.

Cutting staff to the bone seems it was a step long overdue. I do wonder to what extent the delay in that bit of recognition of reality was a function of sustaining real hope the current R&D effort would prove out any value, in time, and to what extent it was more a function of institutional inertia, or, of Bay taking care of the people instead of preserving the support structures.

Might be interesting to note where the cast of people who are leaving... end up going.

My interest here is now down to the level of having a passing interest... worth watching it more to see how Bay manages their people and properties, and to see how they manage the market focused relationships with the core assets in people, including their investors, than for any other reason.

Events we see here give me many more reasons to ask questions about Bay than about VIAP...

Cut labor force!
5. Troubled VIA Pharmaceuticals axes all but six workers
By John Carroll

Staring down a multimillion-dollar loan repayment deadline, troubled VIA Pharmaceuticals has borrowed some more money and time after whittling away about two thirds of its small workforce, reducing its staff to six in a restructuring.

According to the San Francisco Business Times, VIA pledged all of its assets to secure a $10 million loan from Bay City Capital a year ago and owed the principal and interest today. "The Company will not be able to repay the loan when it becomes due on April 1, 2010," VIA reported to the SEC. At the end of last year the company had a deficit of $81 million and $2.2 million of cash on hand.

In a release yesterday, VIA said it was taking a $1.25 million draw from a $3 million secured note with Bay City, giving it enough cash to continue operating into the third quarter of this year.

"VIA's pipeline takes a novel approach to the treatment of major cardiovascular and metabolic diseases, including atherosclerosis and diabetes," said CEO Lawrence K. Cohen, Ph.D., in a prepared statement "By focusing our workforce on a core research and development team and raising this new financing, we have provided additional time to explore opportunities for advancing these promising product candidates, including strategic partnerships or additional financings."

- here's VIA's release
- and here's the report from the San Francisco Business Times

Related Articles:
VIA touts Phase II data
VIA gets $10M in financing
Corautus Genetics to merge with VIA Pharma

015-0195 intraday's range

0155

017 NOW!

I should note that I don't think that the effort made at VIAP was a failure. Of course, it also wasn't a big success... for investors. It was always a very high risk effort, and it seems that it was one that just didn't pan out.

What happened here was GOOD SCIENCE... which, unfortunately for share holders, generated some seriously good and important learning points about the issues they studied, which ended up showing that the state of the art in the science they had based their concepts on... was significantly incomplete... but didn't seem to generate much immediate potential for big new products and massive revenue.

Early stage drug research and development is a high risk affair. Here, the investors money ended up paying to generate scientific progress... not a blockbuster new drug, which might have resulted were they spot on in their entering assumptions.

It looks to me like they took a good honest swing at it and missed... not for lack of trying or lack of skill... and I don't have any problem with that at all. I didn't make any money here by holding VIAP shares... but, I count it still as one of the more successful failures I've seen and been involved with. This was a really good thing to have allocated and lost a little bit of the high end of the risk pool money on.

I hope they find a way to salvage the remnants that they can and make something of them. I hope they figure it out and solve the new puzzles in a way that lets them hit it out of the park on the next go... and hope those still holding now are able to benefit from that effort in the future...

But, for me, I'm going to wait to see if and how they intend to retool it and refocus it... before deciding that it is worth throwing any more risk $$$ at it. For now, it looks like the primary problem is a disconnect between past expectations and the reality of what they have and where they are... along with the reality of the market we are in. I'm not following the thread in the result from what they learned here in the science project. Until they are ready to talk about that... I don't see what ELSE there is to talk about ?

What ? What publicity ? Vicious shorts ? Ummm ? Where? Bashers tirelessly savaging the company ? What are you seeing that I'm not ? I don't see anyone is even paying attention ?

VIAP is about as far off the well trod path of the mainstream as you can possibly get ? There are fewer than a dozen posts total, here, in the last month, with four of those being from you and two of them from me ?

ZZZzzzzz ?

All I see is a continuation pattern of a stock that clearly is twisting in the wind while their key sponsor dithers and tightens the reigns more and more over time, while their short term month to month financing is converted into more and more share dilution, and then, the too predictable response you should expect to see when a stock is being de-listed ?

If this issue is being "beaten down" by the market actors playing here, the only ones with enough interest to make the effort in doing that... are the insiders.

I think you generally need to carefully consider what it is that the insiders are doing, and why they are doing it, as they are, and when they are... and then try to align your interest with theirs as best you can, IF you think they are likely to find a way to make a success that will create a benefit for themselves...

If you figure out what they are doing, and how, and figure out how to do align your interest with theirs, here... let me know ?

For now, I don't have a good enough bead on this... not watching closely enough... to know what the timing issues are, or what the forward risks in the current financing package are, especially following the NASDAQ de-listing. I assume that will make any future money they get cost quite a lot more.

Otherwise ? What else is there to be surprised about ? Was it surprising that they didn't hold a party to announce "WELCOME TO PINKIE LAND, VIAP HOLDERS" ???

IF the plan here is for a takedown being executed by the insiders, Bay et al, etc., prior to popping the "really good news" about the results of the extended Phase II trials ? It will be vastly easier for them to do whatever it is they want to do with this as a pink.

For now, I'm not buying the insider driven conspiracy theory purposed to take all the shares in dilution before all the really good news starts coming out.

It simply looks like they seriously whiffed on the effort they had made... because the science they based their effort on wasn't nearly close enough... and since then they haven't been able to put the wheels back on it in convincing fashion.

For those here still holding shares and hoping for better, soon... I hope I'm wrong. I just don't see a solid reason to expect good news will be coming out of the blue any time soon.

I haven't called to chat with anyone at the company in a long time. If you are holding out hope for a near term change in their future prospects, either on the technical side or in the financing package, I'd call and chat with them to see what they say about the direction they are heading now... and what needs to happen to make that sort of change in fortunes possible. If you do that... post it here to share with us ?

Otherwise, I expect that this already well off the main path issue is likely to trade as an even more well off the path pinkie from here... so that the financing schedules, the burn rates, and the charts probably matter more than what they are doing in the lab right now ?

There is an orchestrated effort to short to death; various paid promoters conguragulating themselves for dropping price over 30 percent with their sell publicity.. fuvking ..

On 12/29/09, VIA Pharmaceuticals, Inc. (Nasdaq:VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and NASDAQ would initiate procedures to delist the Company's common stock.

VIAP is delisted, what will happen now? Will it be traded today or suspended till the 4th of January 2010?

They've changed the month to month lease into a long term two month deal ?

Wooohooo ?

/sarcasm

Bay is still obviously just dinking around, here, which leaves you needing to know a bit more than it seems we do about the drivers in their consideration.

8K Filing is out
http://ih.advfn.com/p.php?pid=nmona&cb=1261577296&article=40862532&symbol=N^VIAP

Hopefully!

GLTY.

Hopefully some positive PR soon. GLTA!

Nice move today...

GLTA.

I don't know...

I'm still not able to avoid being made suspicious re the nature of what seems a highly dilutive, basically day to day financing deal with their sposor that is in place now... and I note the accelerating trend in distribution since the run up in June.

I don't expect that the effort that was made to bring new targets in house should be seen in any way as a negative... rather than as a potential benefit available to VIAP from knowing more about those targets, and their relationship to current research results, given new awareness of the nature of the problems they address that others may not have. But, that still doesn't give me many warm fuzzies about the near term nature of the commitment that the financiers at Bay are NOT making here yet, based on expectations tied to wrapping up the final elements in the current phase II.

I don't think the results that will be reported out after wrapping up the current phase II are going to prove to be much of a surprise... at least not to anyone at Bay. Maybe it is going to be a big deal... and they are just downplaying it now, posturing it as if they think there is WAY more risk than exists, in order to gain a larger benefit from diluting your current interest now, with a tenuous day to day financing arrangement.

Doesn't "feel" to me like it is only that, though...

I don't see much has changed since my last post here, a bit over two months ago:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=41841586

The one thing I see that does look a bit different from then... is the look in the short term charts. Maybe it will pop back up nearer to $0.50 again in the near term... or at least level off here, and stop the slide, with a move back to the top of the bands. Still not feeling it... when Bay could still pull the plug on it at any time. Maybe they'll only do that right after the phase II is wrapped up ?

For now I'll wait and see what happens... a resumption of the slide... or a pinching of bollies before a pop or a drop ?

Might be a trade there... but... I'm not here to trade the market noise, rather than because of an interest in the potential for them to hit it out of the park. A major success in a drug candidate that the phase II shows the majors will have to own... would be nice. I'm not looking for the bunt and a throw to make the out at first... that comes with moving back to re-starting early stage trials with new round of drug candidates.

If that sort of a homerun candidate is what they still have on the line with the current Phase II trial extension... I'll grant you that Bay really ARE doing a pretty good hand playing this hand more like it is a game of poker.

Even better -- early next year we get trial results! :)

GLTY.

Completion and up 4 cents!
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
Date : 12/03/2009 @ 9:00AM
Source : PR Newswire
Stock : (VIAP)
Quote : 0.34 0.04 (13.33%) @ 7:22AM




VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291

Trial Utilizes Positron Emission Tomography with Flurodeoxyglucose Tracer (FDG-PET) Non Invasive Imaging

SAN FRANCISCO, Dec. 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (NASDAQ:VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

The FDG-PET trial enrolled 52 patients and was carried out at five sites in the US and Canada including Massachusetts General Hospital, Mount Sinai School of Medicine, University of Massachusetts, Winthrop University Hospital and Montreal Heart Institute. The study is designed to measure the impact of VIA-2291 on reducing inflammation in carotid plaque in treated patients. Patients were enrolled following an acute coronary syndrome event, such as heart attack or stroke, into the 24 week, randomized, double blind, placebo-controlled study. Endpoints in the study include reduction in atherosclerotic plaque inflammation as measured by serial FDG-PET scans. Completion of the data analysis and presentation of clinical trial results are anticipated in early 2010.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com/.

Ali the Angel; cool; thnx!